ERBB2 and invasive breast carcinoma: This cohort included the patients with a pre-treatment breast core biopsy with HER2 positive invasive breast carcinoma who then received neoadjuvant targeted therapy with trastuzumab ± pertuzumab prior to definitive surgery.